Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

bioRxiv : the preprint server for biology·2026
Same author

M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells.

Cancer letters·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same author

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Blood cancer discovery·2025
Same author

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same author

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Signal transduction and targeted therapy·2025

Related Experiment Video

Updated: Mar 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

MUC1 in hematological malignancies.

Dina Stroopinsky1, Donald Kufe2, David Avigan1

  • 1a Beth Israel Deaconess Medical Center , Harvard Medical School , Boston , MA , USA ;

Leukemia & Lymphoma
|June 28, 2016
PubMed
Summary
This summary is machine-generated.

Mucin1 (MUC1) is an oncogenic protein driving cancer growth and spread. Targeting MUC1 offers a promising therapeutic strategy for hematologic malignancies, showing effectiveness alone and with other treatments.

Keywords:
AMLMUC1ROSmultiple myeloma

More Related Videos

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.5K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Experiment Videos

Last Updated: Mar 18, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.5K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Mucin1 (MUC1) is an oncogenic transmembrane protein implicated in cancer progression.
  • MUC1 interacts with key signaling pathways in hematologic malignancies.
  • MUC1 plays a critical role in leukemia stem cell function and myeloid differentiation.

Purpose of the Study:

  • To review the role of MUC1 in hematologic malignancies.
  • To explore therapeutic strategies targeting MUC1 in these cancers.

Main Methods:

  • Literature review of MUC1's function and therapeutic targeting in hematologic malignancies.

Main Results:

  • MUC1 promotes cancer cell proliferation, survival, and invasion.
  • MUC1 inhibition induces tumor cell death in preclinical models.
  • MUC1 targeting demonstrates synergistic effects with other therapeutic agents.

Conclusions:

  • MUC1 is a significant therapeutic target in hematologic malignancies.
  • Targeting MUC1 presents a viable strategy for cancer treatment, enhancing efficacy with combination therapies.